Immune Cell Therapy for Advanced Solid Tumors

Prior treatment

• Prior receipt of any salvage chemotherapy, implanted intraperitoneal chemotherapy, targeted therapy, or biological immunotherapy (except: patients whose disease progressed more than 6 months after completing adjuvant, neoadjuvant, or radiosensitizing chemotherapy, or more than 1 month after intraperitoneal chemoperfusion/wash, are eligible, provided chemotherapy-related toxicities have recovered to Grade 1 or below, excluding alopecia).
• Major surgical procedure within 4 weeks prior to enrollment, with incomplete recovery from side effects.

Other illness

• History of any active malignancy within 5 years, except for the specific cancer under investigation in this trial and cured localized tumors such as carcinoma in situ of the cervix, basal cell carcinoma of the skin, and prostate carcinoma in situ.
• Inability to tolerate peripheral blood collection due to various reasons (e.g., severe coronary heart disease, inability to establish peripheral venous access).
• Severe cardiovascular disease, including uncontrolled hypertension, unstable angina, history of myocardial infarction within the past 6 months, congestive heart failure \> NYHA (New York Heart Association) Class III, or severe arrhythmia.
• Any active autoimmune disease or history of autoimmune diseases (e.g., but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism; Patients with vitiligo; Patients with childhood asthma that has completely resolved in adulthood without any intervention are eligible; Asthma requiring bronchodilator medical intervention is excluded). Patients are eligible if: they have a history of autoimmune-related hypothyroidism and are on stable thyroid hormone replacement therapy; or have type I diabetes controlled by insulin therapy.
• History of drug allergy.
• History of organ transplantation.
• Any other condition that, in the investigator's judgment, would make the participant unsuitable for the study.

Lab values

• Active infection, unexplained fever ≥ 38.5°C within 7 days prior to medication, or baseline white blood cell count \> 15×10⁹/L; OR any severe acute or chronic infection requiring systemic antibacterial, antifungal, or antiviral therapy at screening (except for active hepatitis).

Other

• An individual who meets any of the following criteria will be excluded from participation in this study:
• Presence of more than a small amount of pericardial effusion, or uncontrolled pleural or peritoneal effusion, defined as: detectable by physical examination at screening, or requiring therapeutic paracentesis during the screening period.
• Pregnant or lactating women; OR women of childbearing potential or men with pregnant partners who are unwilling to use adequate contraception during the planned trial period (from the screening visit until 120 days after the last study treatment).

• To be eligible to participate in this study, an individual must meet all of the following criteria:
• The participant must voluntarily participate in the study and provide written informed consent。
• Age ≥ 18 years, male or female.
• Histologically and/or cytologically confirmed locally advanced or metastatic solid tumor: lung cancer, liver cancer, colorectal cancer, or breast cancer.
• ECOG (Eastern Cooperative Oncology Group) performance status score ≤ 2.
• Life expectancy ≥ 3 months.
• Has not received any other cellular immunotherapy within 3 months prior to enrollment.
• Has at least one measurable lesion according to RECIST (Response Evaluation Criteria in Solid Tumors) Version 1.1.
• Adequate organ function, defined as follows:
  • Hematology:
  • White Blood Cell (WBC) count \> 3.5 × 10⁹/L Lymphocyte count \> 0.9 × 10⁹/L Monocyte count \> 0.16 × 10⁹/L Absolute Neutrophil Count (ANC) \> 1.5 × 10⁹/L Platelet (PLT) count \> 75 × 10⁹/L Hemoglobin (HB) \> 75 g/L Blood Biochemistry： Total bilirubin ≤ 1.5 × ULN (Upper Limit of Normal) Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) ≤ 2.5 × ULN (≤ 5 × ULN if liver metastases are present)
  • Coagulation:
  • Prothrombin Time (PT) and International Normalized Ratio (INR) ≤ 1.5 × ULN